We know that throughout the course of the development of the biotechnology industry history has indeed had a habit of repeating itself. Exactly five years ago the industry was digesting the news that New York-based Pfizer Inc. was shelling out a massive $68 billion to acquire Wyeth – a deal that represented at the time one of the largest big pharma-big pharma transactions in almost a decade. Read More
The first quarter earnings season kicked off last week with investors looking for strong financial results from the leading companies to stabilize the uncertainty that has surrounded the biotech sector these past few weeks. Read More
